Vivos Therapeutics (VVOS) PT Raised to $2.90 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts VVOS Hot Sheet
Price: $0.11 -8.33%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Ascendiant Capital analyst Lucas Ward raised the price target on Vivos Therapeutics (NASDAQ: VVOS) to $2.90 (from $2.80) while maintaining a Buy rating.
You May Also Be Interested In
- CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
